1. Home
  2. OSRH vs LNAI Comparison

OSRH vs LNAI Comparison

Compare OSRH & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

N/A

Current Price

$0.51

Market Cap

18.4M

Sector

N/A

ML Signal

N/A

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.19

Market Cap

18.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSRH
LNAI
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
18.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OSRH
LNAI
Price
$0.51
$0.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
380.7K
298.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.18
52 Week High
$4.33
$1.66

Technical Indicators

Market Signals
Indicator
OSRH
LNAI
Relative Strength Index (RSI) 52.64 22.26
Support Level $0.45 N/A
Resistance Level $0.74 $1.11
Average True Range (ATR) 0.05 0.05
MACD 0.02 -0.01
Stochastic Oscillator 62.57 9.12

Price Performance

Historical Comparison
OSRH
LNAI

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: